- 专利标题： Method of treating cancer comprising administration of anti-HER2 antibody-drug conjugate
-
申请号： US16997613申请日： 2020-08-19
-
公开(公告)号： US11261261B2公开(公告)日： 2022-03-01
- 发明人: Hiroyuki Naito , Yusuke Ogitani , Takeshi Masuda , Takashi Nakada , Masao Yoshida , Shinji Ashida , Koji Morita , Hideki Miyazaki , Yuji Kasuya , Ichiro Hayakawa , Yuki Abe
- 申请人： DAIICHI SANKYO COMPANY, LIMITED
- 申请人地址： JP Tokyo
- 专利权人： DAIICHI SANKYO COMPANY, LIMITED
- 当前专利权人： DAIICHI SANKYO COMPANY, LIMITED
- 当前专利权人地址： JP Tokyo
- 代理机构： Foley & Lardner LLP
- 优先权： JP2014-017777 20140131,JP2014-168944 20140822,JP2014-227886 20141110
- 主分类号： A61K47/68
- IPC分类号： A61K47/68 ; A61K39/395 ; A61K31/4745 ; A61K39/00 ; C07K16/32 ; C07D491/22 ; C07K16/28 ; C07K16/30 ; C07D491/052
摘要：
As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
公开/授权文献
信息查询
IPC分类:
